The role of HMGB1 in digestive cancer.

[1]  E. Klenova,et al.  L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes , 2023, Oncoimmunology.

[2]  Guochun Chen,et al.  T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases. , 2023, International immunopharmacology.

[3]  X. Shuai,et al.  Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis. , 2023, Acta biomaterialia.

[4]  Qiujing Yu,et al.  Nuclear Fructose‐1,6‐Bisphosphate Inhibits Tumor Growth and Sensitizes Chemotherapy by Targeting HMGB1 , 2023, Advanced science.

[5]  Ming Lu,et al.  HMGB1 Positive Feedback Loop Between Cancer Cells and Tumor-Associated Macrophages Promotes Osteosarcoma Migration and Invasion. , 2023, Laboratory investigation; a journal of technical methods and pathology.

[6]  Shuchai Zhu,et al.  Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K/AKT/FOXO3A signaling pathway in ESCC , 2022, Journal of Translational Medicine.

[7]  Shuchai Zhu,et al.  HMGB1 induces radioresistance through PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma , 2022, Molecular Biology Reports.

[8]  Ming-ze Ma,et al.  HMGB1 overexpression promotes a malignant phenotype and radioresistance in ESCC , 2022, Journal of Cancer.

[9]  Xiaoxi Huang,et al.  VPS9D1-AS1 overexpression amplifies intratumoral TGF-β signaling and promotes tumor cell escape from CD8+ T cell killing in colorectal cancer , 2022, bioRxiv.

[10]  Lu Zhang,et al.  Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy , 2022, International journal of biological sciences.

[11]  J. Zhang,et al.  miR-495-3p depresses cell proliferation and migration by downregulating HMGB1 in colorectal cancer , 2022, World Journal of Surgical Oncology.

[12]  E. Otsuji,et al.  Role of Extracellular High-Mobility Group Box-1 as a Therapeutic Target of Gastric Cancer , 2022, International journal of molecular sciences.

[13]  Li Zhang,et al.  Corilagin induces apoptosis and inhibits HMBG1/PI3K/AKT signaling pathways in a rat model of gastric carcinogenesis induced by methylnitronitrosoguanidine , 2022, Environmental toxicology.

[14]  Jian Sun,et al.  Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42 via the HMGB1/RAGE axis , 2022, Human & experimental toxicology.

[15]  Gang Dai,et al.  Long non-coding RNA DCST1-AS1/hsa-miR-582-5p/HMGB1 axis regulates colorectal cancer progression , 2021, Bioengineered.

[16]  Kecheng Zhang,et al.  An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity , 2021, Signal Transduction and Targeted Therapy.

[17]  P. Zhou,et al.  Vitexin Inhibits Gastric Cancer Growth and Metastasis through HMGB1-mediated Inactivation of the PI3K/AKT/mTOR/HIF-1α Signaling Pathway , 2021, Journal of gastric cancer.

[18]  Jian-hui Sun,et al.  The inhibitory receptor Tim-3 regulates sepsis-induced immunosuppression by inhibiting activation of the NF-κb/TNF-α signaling pathway in CD4 T lymphocytes. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Xia-wei Tian,et al.  Epigenetic Regulator KDM4D Restricts Tumorigenesis via Modulating SYVN1/HMGB1 Ubiquitination Axis in Esophageal Squamous Cell Carcinoma , 2021, Frontiers in Oncology.

[20]  Zhigang Xu,et al.  Microenvironment‐Responsive Prodrug‐Induced Pyroptosis Boosts Cancer Immunotherapy , 2021, Advanced science.

[21]  Leo Y. C. Yan,et al.  Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma , 2021, Angiogenesis.

[22]  Xueqin Li,et al.  Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFκB signaling , 2021, Cell Death & Disease.

[23]  Yang Liu,et al.  Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells , 2021, Journal of Nanobiotechnology.

[24]  Xiaoling Zhang,et al.  GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ERα-positive breast cancer cells , 2021, Aging.

[25]  W. Fiedler,et al.  High Mobility Group Box 1 (HMGB1) Induces Toll-Like Receptor 4-Mediated Production of the Immunosuppressive Protein Galectin-9 in Human Cancer Cells , 2021, Frontiers in Immunology.

[26]  D. Philpott,et al.  How autophagy controls the intestinal epithelial barrier , 2021, Autophagy.

[27]  V. Frisardi,et al.  Metabolic Syndrome and Autophagy: Focus on HMGB1 Protein , 2021, Frontiers in Cell and Developmental Biology.

[28]  Chao Wu,et al.  CCRL2 promotes antitumor T-cell immunity via amplifying TLR4-mediated immunostimulatory macrophage activation , 2021, Proceedings of the National Academy of Sciences.

[29]  Jie Ning,et al.  Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma , 2021, Frontiers in Immunology.

[30]  Yu-rong Zou,et al.  HMGB1-TLR4-IL-23-IL-17A axis accelerates renal ischemia-reperfusion injury via the recruitment and migration of neutrophils. , 2021, International immunopharmacology.

[31]  Chenlong Song,et al.  HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis , 2021, Journal of Experimental & Clinical Cancer Research.

[32]  H. Arab,et al.  Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK/mTOR, HMGB1/RAGE and Nrf2/HO-1 pathways. , 2021, Chemico-biological interactions.

[33]  Zhenyu Cheng,et al.  High mobility group box 1 regulates gastric cancer cell proliferation and migration via RAGE-mTOR/ERK feedback loop , 2021, Journal of Cancer.

[34]  Y. Lou,et al.  The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway , 2021, Bioengineered.

[35]  S. Ozawa,et al.  Progress in Multimodal Treatment for Advanced Esophageal Squamous Cell Carcinoma: Results of Multi-Institutional Trials Conducted in Japan , 2020, Cancers.

[36]  W. Fiedler,et al.  Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells , 2020, Aging.

[37]  Chang-ming Huang,et al.  An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer , 2020, Nature Communications.

[38]  L. Varani,et al.  Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity , 2020, Frontiers in Immunology.

[39]  Asma Ahmed,et al.  Targeting immunogenic cell death in cancer , 2020, Molecular oncology.

[40]  Fachao Zhi,et al.  HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway , 2020, Journal of Hematology & Oncology.

[41]  Min Goo Lee,et al.  Secretory autophagy machinery and vesicular trafficking are involved in HMGB1 secretion , 2020, Autophagy.

[42]  Hai-hua Luo,et al.  Internalization of HMGB1 (High Mobility Group Box 1) Promotes Angiogenesis in Endothelial Cells , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[43]  M. Nasr-Esfahani,et al.  Receptor for Advanced Glycation End Products Acts as a Fuel to Colorectal Cancer Development , 2020, Frontiers in Oncology.

[44]  Md Nazmul Haque,et al.  Role of the CXCR4-SDF1-HMGB1 pathway in the directional migration of cells and regeneration of affected organs , 2020, World journal of stem cells.

[45]  Zhihua Liu,et al.  EIF3H promotes aggressiveness of esophageal squamous cell carcinoma by modulating Snail stability , 2020, Journal of experimental & clinical cancer research : CR.

[46]  M. Bianchi,et al.  The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration , 2020, Frontiers in Immunology.

[47]  Hongyan Ren,et al.  Tumor cell-derived autophagosomes (DRibbles)-activated B cells induce specific naïve CD8+ T cell response and exhibit antitumor effect , 2020, Cancer Immunology, Immunotherapy.

[48]  Xianjun Yu,et al.  Ferroptosis, necroptosis, and pyroptosis in anticancer immunity , 2020, Journal of Hematology & Oncology.

[49]  H. Grabsch,et al.  Gastric cancer , 2020, The Lancet.

[50]  Wei Liu,et al.  Extracellular Vesicles From Gastric Cancer Cells Induce PD-L1 Expression on Neutrophils to Suppress T-Cell Immunity , 2020, Frontiers in Oncology.

[51]  E. Otsuji,et al.  Involvement of Intracellular and Extracellular High-Mobility Group Box-1 in the Progression of Esophageal Squamous Cell Carcinoma , 2020, Annals of Surgical Oncology.

[52]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[53]  Pengfei Wu,et al.  Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis , 2020, Cancer biology & medicine.

[54]  G. Murray,et al.  Novel biomarkers for risk stratification of Barrett’s oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype , 2019, British Journal of Cancer.

[55]  K. Vasquez,et al.  Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses. , 2019, DNA repair.

[56]  Jia Liu,et al.  TLR2 Stimulation Increases Cellular Metabolism in CD8+ T Cells and Thereby Enhances CD8+ T Cell Activation, Function, and Antiviral Activity , 2019, The Journal of Immunology.

[57]  Zi-Zhen Zhang,et al.  METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer , 2019, Molecular Cancer.

[58]  J. Ting,et al.  Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10-producing regulatory B cells. , 2019, The Journal of clinical investigation.

[59]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[60]  Rui Zhang,et al.  Curcumin inhibits the lymphangiogenesis of gastric cancer cells by inhibiton of HMGB1/VEGF-D signaling , 2019, International journal of immunopathology and pharmacology.

[61]  T. Billiar,et al.  Location is the key to function: HMGB1 in sepsis and trauma‐induced inflammation , 2019, Journal of leukocyte biology.

[62]  Xiaorong Zhu,et al.  Intestinal epithelial HMGB1 inhibits bacterial infection via STAT3 regulation of autophagy , 2019, Autophagy.

[63]  Yanyan Chen,et al.  miR-129-5p attenuates cell proliferation and epithelial mesenchymal transition via HMGB1 in gastric cancer. , 2019, Pathology, research and practice.

[64]  M. Russo,et al.  HMGB1 and repair: focus on the heart , 2019, Pharmacology & therapeutics.

[65]  Min Fu,et al.  Exosomes in gastric cancer: roles, mechanisms, and applications , 2019, Molecular Cancer.

[66]  Tie-niu Song,et al.  Tumor-derived exosomal HMGB1 promotes esophageal squamous cell carcinoma progression through inducing PD1+ TAM expansion , 2019, Oncogenesis.

[67]  H. Ling,et al.  Autophagy and its role in gastric cancer. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[68]  L. Gai,et al.  HMGB1‐RAGE signaling facilitates Ras‐dependent Yap1 expression to drive colorectal cancer stemness and development , 2018, Molecular carcinogenesis.

[69]  Dinghu Zhang,et al.  PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells , 2018, International journal of nanomedicine.

[70]  Lihua Jiang,et al.  The progression of HMGB1-induced autophagy in cancer biology , 2018, OncoTargets and therapy.

[71]  Guihua Chen,et al.  Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1+ regulatory B cell expansion , 2018, Journal of Immunotherapy for Cancer.

[72]  E. Vellenga,et al.  The multifaceted role of autophagy in cancer and the microenvironment , 2018, Medicinal research reviews.

[73]  H. Qian,et al.  Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration , 2018, Molecular Cancer.

[74]  S. Chiang,et al.  HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer , 2018, Cell Death & Disease.

[75]  Hong Zhang,et al.  LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway , 2018, Molecular Cancer.

[76]  Q. Ma,et al.  Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway , 2018, International journal of oncology.

[77]  Xinchen Sun,et al.  High‐mobility group box 1 protein modulated proliferation and radioresistance in esophageal squamous cell carcinoma , 2018, Journal of gastroenterology and hepatology.

[78]  Peng Zhang,et al.  Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression , 2018, Oncogenesis.

[79]  Long-Bang Chen,et al.  Wnt signaling induces radioresistance through upregulating HMGB1 in esophageal squamous cell carcinoma , 2018, Cell Death & Disease.

[80]  J. Utikal,et al.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression , 2018, Front. Immunol..

[81]  D. Suren,et al.  High Mobility Group Box 1 (HMGB1) expression in gastric adenocarcinomas. , 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[82]  L. Varani,et al.  High mobility group box 1 (HMGB1) acts as an “alarmin” to promote acute myeloid leukaemia progression , 2018, Oncoimmunology.

[83]  M. Lippman,et al.  Targeting RAGE Signaling in Inflammatory Disease. , 2018, Annual review of medicine.

[84]  Jingtao Li,et al.  Matrine Ameliorates Colorectal Cancer in Rats via Inhibition of HMGB1 Signaling and Downregulation of IL-6, TNF-α, and HMGB1 , 2018, Journal of immunology research.

[85]  M. Bianchi,et al.  High‐mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair , 2017, Immunological reviews.

[86]  Y. Soon,et al.  Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. , 2017, The Cochrane database of systematic reviews.

[87]  H. Chung,et al.  High‐mobility group box‐1 contributes tumor angiogenesis under interleukin‐8 mediation during gastric cancer progression , 2017, Cancer science.

[88]  P. Heeger,et al.  TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement , 2017, The Journal of Immunology.

[89]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[90]  J. V. van Leeuwen,et al.  NELL-1, HMGB1, and CCN2 Enhance Migration and Vasculogenesis, But Not Osteogenic Differentiation Compared to BMP2. , 2017, Tissue engineering. Part A.

[91]  Wenqing Gao,et al.  Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. , 2017, Trends in biochemical sciences.

[92]  Hong Zhou,et al.  The Role of TLR4 on B Cell Activation and Anti-β 2GPI Antibody Production in the Antiphospholipid Syndrome , 2016, Journal of immunology research.

[93]  A. Thorburn,et al.  Therapeutic Targeting of Autophagy☆ , 2016, EBioMedicine.

[94]  Lin Jiang,et al.  Treatment effects of oxaliplatin combined with gemcitabine on colorectal cancer and its influence on HMGB1 expression , 2016, Oncology letters.

[95]  M. Karin,et al.  Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment , 2016, Cell.

[96]  Aimin Li,et al.  NIK- and IKKβ-binding protein promotes colon cancer metastasis by activating the classical NF-κB pathway and MMPs , 2016, Tumor Biology.

[97]  Jun Dong,et al.  Prognostic potential of an immune score based on the density of CD8+ T cells, CD20+ B cells, and CD33+/p-STAT1+ double-positive cells and HMGB1 expression within cancer nests in stage IIIA gastric cancer patients , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[98]  J. Locasale,et al.  The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.

[99]  L. Jia,et al.  Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan , 2016, Cell Death and Disease.

[100]  K. Tracey,et al.  HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4 , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[101]  Hoguen Kim,et al.  Combined targeting of high‐mobility group box‐1 and interleukin‐8 to control micrometastasis potential in gastric cancer , 2015, International journal of cancer.

[102]  H. Qun,et al.  Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer , 2015, Cell & Bioscience.

[103]  M. Lotze,et al.  Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. , 2015, Journal of hepatology.

[104]  I. Christensen,et al.  The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer , 2015, The EMBO journal.

[105]  Matthew D Gargus,et al.  Human esophageal myofibroblasts secrete proinflammatory cytokines in response to acid and Toll-like receptor 4 ligands. , 2015, American journal of physiology. Gastrointestinal and liver physiology.

[106]  R. Ahmed,et al.  NF-κB Regulates PD-1 Expression in Macrophages , 2015, The Journal of Immunology.

[107]  Z. Bi,et al.  HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway , 2015, Cancer biology & therapy.

[108]  M. Bianchi,et al.  5‐Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells , 2015, International journal of cancer.

[109]  Xiaorong Zhu,et al.  Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. , 2015, The Journal of clinical investigation.

[110]  Jingyuan Fang,et al.  High-mobility group Box 1: A novel inducer of the epithelial–mesenchymal transition in colorectal carcinoma , 2015 .

[111]  Xu Lin,et al.  Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2 , 2015, Oncology reports.

[112]  V. Ehemann,et al.  The HMGB1 protein sensitizes colon carcinoma cells to cell death triggered by pro-apoptotic agents. , 2015, International journal of oncology.

[113]  Haichao Wang,et al.  HMGB1 in health and disease. , 2014, Molecular aspects of medicine.

[114]  K. Tracey,et al.  HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. , 2014, Cancer research.

[115]  S. Esener,et al.  TLR4-dependent activation of dendritic cells by an HMGB1-derived peptide adjuvant , 2014, Journal of Translational Medicine.

[116]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[117]  Nikhil S. Joshi,et al.  TLR4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A Differentially Regulate Effector and Memory CD8+ T Cell Differentiation , 2014, The Journal of Immunology.

[118]  Yubin Kou,et al.  Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo. , 2014, International journal of oncology.

[119]  Tianshu Yang,et al.  High‐mobility group box‐1 and its role in angiogenesis , 2014, Journal of leukocyte biology.

[120]  K. Tominaga,et al.  High-Mobility Group Box 1 Inhibits Gastric Ulcer Healing through Toll-Like Receptor 4 and Receptor for Advanced Glycation End Products , 2013, PloS one.

[121]  Zhen-yu Zhang,et al.  Micrometastasis in gastric cancer. , 2013, Cancer letters.

[122]  M. Bianchi,et al.  HMGB1 and leukocyte migration during trauma and sterile inflammation. , 2013, Molecular immunology.

[123]  K. Tao,et al.  HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection. , 2013, Biochemical and biophysical research communications.

[124]  K. Tracey,et al.  The many faces of HMGB1: molecular structure‐functional activity in inflammation, apoptosis, and chemotaxis , 2013, Journal of leukocyte biology.

[125]  Hua Yu,et al.  B Cells Promote Tumor Progression via STAT3 Regulated-Angiogenesis , 2013, PloS one.

[126]  M. Lotze,et al.  HMGB1: The Central Cytokine for All Lymphoid Cells , 2013, Front. Immunol..

[127]  F. C. Gibson,et al.  Macrophage-Specific TLR2 Signaling Mediates Pathogen-Induced TNF-Dependent Inflammatory Oral Bone Loss , 2013, The Journal of Immunology.

[128]  M. Churchill,et al.  The high mobility group box: the ultimate utility player of a cell. , 2012, Trends in biochemical sciences.

[129]  M. Lotze,et al.  Tumor immunity times out: TIM-3 and HMGB1 , 2012, Nature Immunology.

[130]  H. Fujii,et al.  Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. , 2012, Cancer research.

[131]  H. Yoshiyama,et al.  Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 , 2012, Nature Immunology.

[132]  Kimberley C. W. Wang,et al.  IGF-2R-Mediated Signaling Results in Hypertrophy of Cultured Cardiomyocytes from Fetal Sheep1 , 2012, Biology of reproduction.

[133]  M. Lotze,et al.  Direct molecular interactions between HMGB1 and TP53 in colorectal cancer , 2012, Autophagy.

[134]  Yu Zhentao,et al.  The Expression of High Mobility Group Box 1 is Associated with Lymph Node Metastasis and Poor Prognosis in Esophageal Squamous Cell Carcinoma , 2012, Pathology & Oncology Research.

[135]  H. Oda,et al.  Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells. , 2012, Biochemical and biophysical research communications.

[136]  Simon C Watkins,et al.  p53/HMGB1 complexes regulate autophagy and apoptosis. , 2012, Cancer research.

[137]  Yun Dai,et al.  Tissue factor/activated factor VIIa induces matrix metalloproteinase-7 expression through activation of c-Fos via ERK1/2 and p38 MAPK signaling pathways in human colon cancer cell , 2012, International Journal of Colorectal Disease.

[138]  L. Varani,et al.  HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 , 2012, The Journal of experimental medicine.

[139]  B. Song,et al.  Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC‐803 gastric cancer cells , 2012, Cell biochemistry and function.

[140]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[141]  M. Lotze,et al.  The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. , 2011, Antioxidants & redox signaling.

[142]  Zuqiang Liu,et al.  Knockdown of HMGB1 in Tumor Cells Attenuates Their Ability To Induce Regulatory T Cells and Uncovers Naturally Acquired CD8 T Cell-Dependent Antitumor Immunity , 2011, The Journal of Immunology.

[143]  G. Kroemer,et al.  High-mobility group box 1 is essential for mitochondrial quality control. , 2011, Cell metabolism.

[144]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[145]  K. Tracey,et al.  Endogenous HMGB1 regulates autophagy , 2010, The Journal of cell biology.

[146]  K. Tracey,et al.  HMGB1 Release and Redox Regulates Autophagy and Apoptosis in Cancer Cells , 2010, Oncogene.

[147]  R. Pardi,et al.  Inhibitor of NF-κB Kinases α and β Are Both Essential for High Mobility Group Box 1-Mediated Chemotaxis , 2010, The Journal of Immunology.

[148]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[149]  Y. Yamashita,et al.  HMGB1 attenuates anti-metastatic defence of the liver in colorectal cancer. , 2010, European journal of cancer.

[150]  A. Iwasaki,et al.  Regulation of Adaptive Immunity by the Innate Immune System , 2010, Science.

[151]  M. Lotze,et al.  The Receptor for Advanced Glycation End-products (RAGE) Sustains Autophagy and Limits Apoptosis, Promoting Pancreatic Tumor Cell Survival , 2009, Cell Death and Differentiation.

[152]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[153]  Hoguen Kim,et al.  Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers , 2009, Laboratory Investigation.

[154]  D. Stroncek,et al.  Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer , 2009, Journal of Translational Medicine.

[155]  Š. Pospíšilová,et al.  HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIα , 2009, Nucleic acids research.

[156]  S. Guha,et al.  CXCL8/IL‐8 and CXCL12/SDF‐1α co‐operatively promote invasiveness and angiogenesis in pancreatic cancer , 2009, International journal of cancer.

[157]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[158]  K. Miyake,et al.  TLR accessory molecules. , 2008, Current opinion in immunology.

[159]  L. Zitvogel,et al.  The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy , 2007, Immunological reviews.

[160]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[161]  K. Grasser,et al.  The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins , 2007, Cellular and Molecular Life Sciences.

[162]  Jeon-Soo Shin,et al.  Nucleocytoplasmic Shuttling of HMGB1 Is Regulated by Phosphorylation That Redirects It toward Secretion1 , 2006, The Journal of Immunology.

[163]  M. Presta,et al.  Cutting Edge: Extracellular High Mobility Group Box-1 Protein Is a Proangiogenic Cytokine1 , 2006, The Journal of Immunology.

[164]  Raymond Sawaya,et al.  The role of autophagy in cancer development and response to therapy , 2005, Nature Reviews Cancer.

[165]  S. Joos,et al.  Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas , 2005, Gut.

[166]  Giovanna Angelini,et al.  NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. , 2005, Blood.

[167]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[168]  K. Tracey,et al.  High Mobility Group Box Protein 1: An Endogenous Signal for Dendritic Cell Maturation and Th1 Polarization , 2004, The Journal of Immunology.

[169]  H. Huttunen,et al.  Amphoterin as an extracellular regulator of cell motility: from discovery to disease , 2004, Journal of internal medicine.

[170]  Tiziana Bonaldi,et al.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion , 2003, The EMBO journal.

[171]  D. E. Goll,et al.  The calpain system. , 2003, Physiological reviews.

[172]  H. Kuniyasu,et al.  Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. , 2003, Oncology reports.

[173]  K. Tracey,et al.  HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. , 2002, Gastroenterology.

[174]  M. Beltrame,et al.  Flexing DNA: HMG-box proteins and their partners. , 1998, American journal of human genetics.

[175]  D. Landsman,et al.  The HMG-1 box protein family: classification and functional relationships. , 1995, Nucleic acids research.

[176]  M. Bustin,et al.  The intracellular distribution and function of the high mobility group chromosomal proteins. , 1985, Experimental cell research.

[177]  G. Goodwin,et al.  A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. , 1973, European journal of biochemistry.

[178]  Lanlan Zhou,et al.  Pan-integrin inhibitor GLPG-0187 promotes T-cell killing of mismatch repair-deficient colorectal cancer cells by suppression of SMAD/TGF-β signaling. , 2023, American journal of cancer research.

[179]  Davalyn R. Powell,et al.  Neutrophils in the Tumor Microenvironment. , 2016, Trends in immunology.

[180]  Y. Ye,et al.  © 2012 Landes Bioscience. Do not distribute. Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1 , 2012 .

[181]  M. Lotze,et al.  HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells , 2011, Leukemia.

[182]  Arjan W. Griffioen,et al.  Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1) , 2008, Angiogenesis.

[183]  S. Akira,et al.  Toll-like receptors and innate immunity. , 2006, Journal of molecular medicine.

[184]  T. Sasahira,et al.  Growth Factors, Cytokines, Cell Cycle Molecules Colon Cancer Cell-Derived High Mobility Group 1/Amphoterin Induces Growth Inhibition and Apoptosis in Macrophages , 2005 .

[185]  Hong Wang,et al.  Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1 , 2003, Molecular medicine.